Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15246622 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21416485 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL16266184 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24848129 | 0.99 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23286101 | 0.97 | FAP (0.42) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18244334 | 0.94 | FAP (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18244335 | 0.94 | FAP (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22952275 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24520454 | 0.94 | FAP (0.47) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20808481 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026090578-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | Antharis Therapeutics Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090567-A1 | FLT3-BINDING ANTIBODIES AND METHODS OF USE THEREOF | Antharis Therapeutics Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115303-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | ANTHARIS THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4729617-A1 | APTAMER TARGETING CD25, DRUG CONJUGATE COMPRISING SAME, AND USE THEREOF | Aptamer Sciences Inc. (KR) | 2026-04-22 | — | — | EP | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| EP-4725966-A1 | HUMAN EPIDERMAL GROWTH FACTOR 3 ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI RUOTUO BIOSCIENCES CO., LTD. (CN) | 2026-04-15 | — | — | EP | claimed |
| EP-4720134-A1 | ANTI-CEACAM5/6 DUAL-BINDING ANTIBODIES | Nona Biosciences (Suzhou) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-20220251197-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-08-11 | — | — | US | claimed |
| CN-111617250-B | Multi-ligand drug couplet and application thereof | 同宜医药（苏州）有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114685668-A | Human GPC3 monoclonal antibody and conjugate thereof | 石药集团巨石生物制药有限公司 | 2022-07-01 | — | — | CN | claimed |
| WO-2022111616-A1 | ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 石药集团巨石生物制药有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022105881-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105878-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105879-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105873-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| CN-114191428-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | EGFR, ERBB2, IGSF11 | FAP 4822/4885NPY5R 2241/4885NPY4R 954/4885 |
| US-20260115303-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | CDH1, H1-3, H1-2 | FAP 4033/4885NPY5R 1169/4885NPY4R 1470/4885 |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | FAP 2452/4885NPY5R 4310/4885NPY4R 4780/4885 |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | H1-10, IGSF11, CD99 | FAP 4682/4885NPY5R 2450/4885NPY4R 2837/4885 |
| US-20220251197-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | FAP 3575/4885NPY5R 4516/4885NPY4R 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.